Marc Lajoie, Outpace Bio CEO
Outpace Bio expands cell therapy R&D, nets research collaborations in Seattle
Outpace Bio, a Seattle-based biotech that aims to create cell therapies, has cemented its presence in the Emerald City with a new facility and a pair of local research partnerships with scientific leaders.
The biotech announced Tuesday that it secured a new facility in a 23,000-square-foot space in Seattle’s Dexter Yard to house the company’s R&D efforts. The company now has 53 employees and has grown from a platform company to a pipeline and platform company, both of which require growth and more space, according to Outpace CEO Marc Lajoie in an interview with Endpoints News.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters